personalized diagnostics

IMMS harnesses for point-of-care diagnostics

At the MEDICA 2016 IMMS is presenting its first approaches for the personalized diagnostics of cancer using a prototype device. It was developed in the three-year research project INSPECT which started in June 2016.

Devices performing rapid, reliable, cost-efficient and automated POC...
Devices performing rapid, reliable, cost-efficient and automated POC diagnostics should look like this in the future. IMMS presents a prototype device with live demonstration to showcase its developments for personalized cancer diagnostics.
Source: IMMS

IMMS focusses on the integration of various sensor principles of different biological and chemical measurands into one integrated electronic device for extensive and precise diagnostics. The work is based on cost-efficient standard semiconductor manufacturing processes (CMOS) which IMMS also uses for these new diagnostic approaches.

IMMS adapts its systems to application-specific needs by means of particular functionalisation of surfaces and the use of biocompatible material. These solutions should pave the way for fast, reliable, cost-efficient and automated in-vitro diagnostics, such as early recognition of cancer.

In the INSPECT research project IMMS is developing systems for the early recognition of breast, cervical, prostate and lung cancers using semiconductor chips as well as immunological and cell-based biotechnological methods. IMMS is working on an interdisciplinary interface between biology and microelectronics for signal processing. In addition, further concepts for microelectronic-based point-of-care diagnostics and for personalized cancer immunotherapies are being investigated. IMMS is currently testing the first prototypes of the miniaturized diagnostic devices. The research partners iba Institut für Bioprozess- und Analysenmesstechnik e.V. Heiligenstadt, Senova Gesellschaft für Biowissenschaft und Technik mbH Weimar, CDA GmbH Suhl and X-FAB Semiconductor Foundries AG Erfurt are contributing to the novel solutions. IMMS is coordinating the consortium.

Funding:
The INSPECT project receives funding from the “Land” of Thüringen and the European Union (European Regional Development Fund (ERDF, German EFRE) under the reference 2015 FE 9159.


Source: IMMS

16.11.2016

Read all latest stories

Related articles

Photo

Cancer care

Oncology Nursing: Worldwide knowledge differs greatly

Nurses’ knowledge of cancer and screening processes varies significantly across the globe – potentially resulting in unnecessary deaths where knowledge falls short – new research reports. In…

Photo

Oncology

Blood test detects early stage pancreatic cancer

Pancreatic cancer is currently very difficult to detect while it is still resectable. A new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and…

Photo

Methods, quality assurance, commercial providers issues

Molecular testing takes a huge leap

In terms of success in revolutionary cancer treatment, molecular genetic examination procedures have developed immensely over recent years. They now range from conventional polymerase chain reactions…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
DiaSys Diagnostic Systems - InnovaStar

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH
Exias Medical – e|1 Analyzer

Blood Gases, Electrolyte, Oximetry

Exias Medical – e|1 Analyzer

EXIAS MEDICAL GmbH
INPECO SA – PROTUBE

Other

INPECO SA – PROTUBE

Inpeco SA